ImmunoPrecise Antibodies Ltd. - Common Stock (IPA)
0.4786
-0.0172 (-3.47%)
Immunoprecise Antibodies Ltd is a biotechnology company that specializes in the development and production of high-quality antibodies and related therapeutics for use in various biomedical applications
The company offers a range of services, including custom antibody production, protein engineering, and diagnostic assay development, catering to the needs of researchers and pharmaceutical companies. With a focus on advancing personalized medicine and supporting drug discovery, Immunoprecise Antibodies aims to provide innovative solutions that enhance the effectiveness of therapeutic treatments across multiple disease areas.
![](https://cdn.benzinga.com/files/images/story/2025/01/22/Test-Tube-Row--Concept-Of-Medical-Or-Sci.jpeg?width=1200&height=800&fit=crop)
Immunoprecise shares closed higher on Wednesday after the company announced it developed a new class of GLP-1 therapies.
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/abbott-shutter.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/Procter--Gamble-pg-shutter.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/22/King-County--Washington--United-States--_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2024/06/10/IPA.png?width=1200&height=800&fit=crop)
ImmunoPrecise Antibodies launches BioStrand's LENSaiAPI software, enhancing AI-driven drug discovery and data integration for healthcare and pharmaceutical industries.
Via Benzinga · June 10, 2024
![](https://cdn.benzinga.com/files/images/story/2024/IPA-New.png?width=1200&height=800&fit=crop)
Immunoprecise Antibodies partners with InterSystems to integrate Vector Search of IRIS data platform with BioStrand's LENSai for AI-driven healthcare solutions. Revolutionize drug discovery with precise, scalable data analysis.
Via Benzinga · March 28, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
IPA stock results show that ImmunoPrecise Antibodies missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2024.
Via InvestorPlace · March 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/02/12/screenshot_2024-02-12_at_6.42.23_pm.png?width=1200&height=800&fit=crop)
Even though we speak, listen, read and write every day, language is incredibly complex and ever-evolving. Context is critical to understanding. In the English language, there are a plethora of words that are spelled the same but have vastly different meanings depending on their context.
Via Benzinga · February 12, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Pharming (NASDAQPHAR) is projected to report earnings for its fourth quarter.
Via Benzinga · March 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/07/image49_0.jpg?width=1200&height=800&fit=crop)
Shares of HighPeak Energy, Inc. (NASDAQHPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results.
Via Benzinga · March 7, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/09/screenshot_2024-01-09_at_6.37.14_pm.png?width=1200&height=800&fit=crop)
ImmunoPrecise Antibodies (NASDAQIPA) (“IPA”), a leading company in AI-driven biotherapeutic research and technology, has recently
Via Benzinga · January 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
IPA stock results show that ImmunoPrecise Antibodies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · December 14, 2023
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Live Ventures (NASDAQLIVE) is estimated to report earnings for its fourth quarter. • Jabil NYSE:JBLNYSEJBL)
Via Benzinga · December 14, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/06/campbell_soup_-_logo_0.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&P 500 also fell, dropping, 0.05% to 4,564.73.
Via Benzinga · December 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/06/aerovironment_-_logo.jpg?width=1200&height=800&fit=crop)
Shares of AeroVironment, Inc. (NASDAQAVAV) moved lower during Wednesday’s session following second-quarter results.
Via Benzinga · December 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/06/stock-624712.jpg?width=1200&height=800&fit=crop)
ImmunoPrecise Antibodies Ltd (NASDAQIPA) shares are trading lower by 23% to $1.19 Wednesday afternoon after the company announced pricing of a $1.1 million public offering of common shares at
Via Benzinga · December 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/06/crude_oil_4-_logo.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 while the NASDAQ rose 0.03% to 14,233.77. The S&P 500 also fell, dropping, 0.05% to 4,565.09.
Via Benzinga · December 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/06/image41.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28% to 14,270.30. The S&P 500 also rose, gaining, 0.32% to 4,581.88.
Via Benzinga · December 6, 2023
![](https://investorplace.com/wp-content/uploads/2022/07/shutterstock_636632101.jpg)
Carbon Revolution stock is falling on Wednesday after shares of CREV gained yesterday with plans for a business update conference call.
Via InvestorPlace · December 6, 2023